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Abstract: Autoinflammatory diseases (AIDs) are heterogeneous disorders characterized by dysregulation
in the inflammasome, a large intracellular multiprotein platform, leading to overproduction of
interleukin-1(IL-1)β that plays a predominant pathogenic role in such diseases. Appropriate treatment is
crucial, also considering that AIDs may persist into adulthood with negative consequences on patients’
quality of life. IL-1β blockade results in a sustained reduction of disease severity in most AIDs. A growing
experience with the human IL-1 receptor antagonist, Anakinra (ANA), and the monoclonal anti IL-1β
antibody, Canakinumab (CANA), has also been engendered, highlighting their efficacy upon protean
clinical manifestations of AIDs. Safety and tolerability have been confirmed by several clinical trials and
observational studies on both large and small cohorts of AID patients. The same treatment has been
proposed in refractory Kawasaki disease, an acute inflammatory vasculitis occurring in children before
5 years, which has been postulated to be autoinflammatory for its phenotypical and immunological
similarity with systemic juvenile idiopathic arthritis. Nevertheless, minor concerns about IL-1 antagonists
have been raised regarding their employment in children, and the development of novel pharmacological
formulations is aimed at minimizing side effects that may affect adherence to treatment. The present
review summarizes current findings on the efficacy, safety, and tolerability of ANA and CANA for
treatment of AIDs and Kawasaki vasculitis with a specific focus on the pediatric setting.
Int. J. Mol. Sci. 2019, 20, 1898; doi:10.3390/ijms20081898 www.mdpi.com/journal/ijms
Int. J. Mol. Sci. 2019, 20, 1898 2 of 22
Keywords: Interleukin-1; anakinra; canakinumab; innovative biotechnologies; autoinflammatory disease;
Kawasaki disease; systemic juvenile idiopathic arthritis; personalized medicine; child; pediatrics
1. Introduction
Autoinflammatory diseases (AIDs) are a heterogeneous group of monogenic and multifactorial
diseases characterized by recurrent or chronic inflammation caused by dysregulation of the innate
immune system [1,2]. Most of these disorders have an early onset, ranging from the first h to the first
decade of life. However, due to their rarity, a diagnostic delay is frequently observed [3]. The main
subgroup of AIDs includes different hereditary periodic fever syndromes, such as cryopyrin-associated
periodic syndrome (CAPS), tumor necrosis factor receptor-associated periodic fever syndrome
(TRAPS), hyperimmunoglobulin D syndrome/mevalonate kinase deficiency (HIDS/MKD), and familial
Mediterranean fever (FMF) [2]. These conditions follow an autosomal dominant (CAPS and TRAPS) or
recessive (HIDS/MKD and FMF) hereditary pattern and share a common clinical background marked
by recurrent fever attacks and inflammation involving different sites, such as skin, serosal membranes,
joints, gastrointestinal tract, or central nervous system [4,5]. AA amyloidosis is their most serious
complication in the long-term, with an overall prevalence ranging from 2% to 25% of cases [6]. Many
multifactorial disorders manifest with the same clinical features observed in inherited AIDs and even
share the same pathogenic pathway [7]. In this regard, recurrent fevers with arthritis and cutaneous
rashes are also typical features of systemic juvenile idiopathic arthritis (SJIA), which has been classified
up to now as a category of juvenile idiopathic arthritis, the most common rheumatic disease in
childhood. SJIA can lead to growth retardation, osteoporosis, and life-threatening complications, such
as macrophage activation syndrome (MAS), and is now considered an autoinflammatory condition [8,9].
Recently, an autoinflammatory origin has also been suggested for Kawasaki disease (KD), an acute
self-limited systemic vasculitis usually occurring in children before 5 years and involving medium-sized
vessels, especially coronary arteries, which represents the first cause of childhood-acquired heart
disease in developed countries [10]. Irrespective of the specific underlying pathways, these syndromes
are characterized by an overproduction of interleukin (IL)-1, which initiates the inflammatory cascade
and leads to tissue damage of variable degrees. Therefore, appropriate and effective treatment is
crucial, considering that these conditions may persist into adulthood with negative consequences on
both the patient’s future health and quality of life [11]. Monotherapy blocking IL-1 activity results in a
sustained reduction of disease severity, but chronic treatment is often required to control inflammatory
flares for the lifetime and prevent long-term complications. Therefore, monitoring the safety profile
and tolerability of therapy in children affected by these disorders is of paramount importance since it
may affect adherence to treatment and overall clinical efficacy. In this work, we aimed at providing
current findings on the efficacy, safety, and tolerability of Anakinra (ANA) and Canakinumab (CANA)
for treatment of AIDs and Kawasaki vasculitis with a specific focus on the pediatric setting.
2. IL-1 Blockade in Autoinflammatory Diseases
The IL-1 family includes key cytokines involved in the innate immune response as well as
in the mechanisms of fever and inflammation [12,13]. Namely, IL-1 induces the synthesis of major
inflammatory mediators, such as cyclooxygenase type 2 (COX-2), type 2 phospholipase A, and inducible
nitric oxide synthase, which in turn account for the production of prostaglandin-E2, platelet activating
factor, and nitric oxide [12]. The two major cytokines, IL-1α and IL-1β, exert their pro-inflammatory
effects by binding the IL-1 family receptors, which are characterized by the presence of the Toll-IL-1
receptor (TIR) domain in the cytoplasmic portion [14,15]. In physiological conditions, both IL-1α
and IL-1β bind to type 1 IL-1 receptor (IL-1R1) and to the adaptor protein, IL-1RAcP, in order to
trigger signal transduction [16]. On the contrary, the IL-1 receptor antagonist (IL-1RA) is a competitive
inhibitor that prevents IL-1α and IL-1β from interacting with the IL-1 receptor 1 (IL-1R1). Much less is
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instead known about the type 2 IL-1 receptor (IL-1R2), a decoy receptor for IL-1β, lacking a cytoplasmic
domain, which does not have a signal role, but rather sequesters IL-1β [17]. Most AIDs are caused by
a lacking regulation in the inflammasome, a large intracellular multiprotein platform, leading to an
overproduction of IL-1β that plays a predominant pathogenic role in such disorders [18].
Four biologic drugs blocking IL-1 are currently available [19,20]. Of them, ANA and CANA
have been approved for clinical use in Europe, whereas the soluble decoy IL-1-receptor, rilonacept,
and the human-engineered monoclonal anti-IL-1β, gevokizumab, are not authorized in European
countries. ANA is a human IL-1 receptor antagonist that acts by competitively inhibiting the binding
of IL-1 with the IL-1 type 1 receptor [21]. ANA (Kineret®) is currently approved for the treatment of
rheumatoid arthritis (RA), CAPS, and Still’s disease [21]. In adult, adolescent, and pediatric patients
aged 8 months or older affected by CAPS, ANA is administered at the starting dose of 1 to 2 mg/kg/day
by subcutaneous (s.c.) injection. For the maintenance of response, a regimen of 1 to 2 mg/kg/day is
indicated in the case of a milder disease, whereas in more severe cases, the usual maintenance dose is 3
to 4 mg/kg/day, which can be adjusted to a maximum of 8 mg/kg/day [21]. The absolute bioavailability
of ANA after 70 mg s.c. injection in healthy subjects is around 95%. In RA patients, maximum plasma
concentrations of ANA have been reported at 3 to 7 h after s.c. administration (1 to 2 mg/kg), whereas
the half-life ranges from 4 to 6 h. The clearance of ANA is mainly mediated by the kidney, and
increases along with creatinine clearance [21]. In children with CAPS, the pharmacokinetics of ANA
is significantly influenced by body weight [22]. On the other hand, CANA is a human monoclonal
antibody that specifically binds IL-1β, blocking its interaction with IL-1 receptor and preventing the
consequent inflammatory response [23]. CANA (Ilaris®) is currently approved for the treatment of
periodic fever syndromes in adults, adolescents, and children aged at least 2 years, including CAPS,
TRAPS, FMF, and HIDS/MKD, as well as in the treatment of Still’s disease and gouty arthritis [23].
The recommended starting dose of CANA in adults, adolescents, and children aged 2 years (and older)
is 150 mg for patients with body weight > 40 kg and 2 mg/kg for patients with body weight ≥ 7.5 kg
and ≤ 40 kg. CANA is administered every four weeks as a single dose via s.c. injection. In CAPS
children aged 2 to 4 years with body weight ≥ 7.5 kg and in adolescents and children older than 4 years
with body weight between 7.5 and 15 kg, the starting dose of CANA is 4 mg/kg. In patients with body
weight between 15 kg and 40 kg, the indicated starting dose is 2 mg/kg, whereas in patients weighing
more than 40 kg CANA should be initially administered at the dose of 150 mg [23]. CANA should be
administered every 8 weeks, as a single dose via s.c. injection. Maintenance dose should be defined
based on the initial response [23]. In adults, the peak of serum CANA concentration (Cmax) occurs
approximately 7 days after a single s.c. administration of 150 mg, whereas the mean half-life is around
26 days. The absolute bioavailability of CANA is estimated to be 66%. Body weight significantly
influences both CANA distribution and elimination [23]. In very young children, a modest increase in
the turnover rate of IL-1β has been observed. In pediatric patients, no age-related variations of CANA
clearance and volume of distribution can be found after correction for body weight [24]. A schematic
representation of IL-1 inhibition with CANA and ANA is depicted in Figure 1.
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Figure 1. Strategies for IL-1 blockade with Anakinra and Canakinumab. (A) Interleukin (IL)-1 binds 
to type 1 IL-1 receptor (IL-1R1) and to the adaptor protein, IL-1RAcP, in order to trigger signal 
transduction. (B) The recombinant human IL-1R1 antagonist, Anakinra, directly competes with IL-1 
for binding to the IL-1R1, blocking the biological activity of IL-1. (C) The human monoclonal IgG1 
antibody, Canakinumab, selectively neutralizes IL-1β and inhibits its binding to the IL-1 receptor. 
3. Cryopyrin-Associated Periodic Syndrome 
CAPS includes a spectrum of apparently distinct inflammatory disorders of increasing severity: 
Familial cold autoinflammatory syndrome (FCAS), Muckle-Wells syndrome (MWS), and chronic 
infantile neurological, cutaneous, articular (CINCA) syndrome/neonatal-onset multisystem 
inflammatory disease (NOMID), all caused by mutations in NLRP3, the gene encoding cryopyrin, a 
component of the IL-1 inflammasome that regulates the production of IL-1β [25]. Therapeutic 
strategies specifically aimed at blocking IL-1 have been widely evaluated in CAPS patients (Table 1). 
Namely, the efficacy and safety profile of CANA in CAPS have been extensively assessed, both in 
clinical trials as well as in the real clinical practice. In a 48-week double-blind placebo-controlled 
randomized withdrawal study, the use of CANA (administered s.c. at the dose of 150 mg or 2 mg/kg 
for patients weighing 40 kg or less) every 8 weeks was evaluated in a cohort of 35 CAPS patients [26]. 
Namely, 4 patients were aged 4 to 16 years, whereas the remaining 31 patients were aged 17 to 75 
years. Of them, 26 had history of a previous anti-IL1 treatment. A single dose of CANA accounted 
for complete response in 34 patients (97%); of note, CAPS symptoms significantly improved within 
24 hours in patients who had a response. Regarding patients entering the double-blind phase, all the 
15 patients continuing CANA treatment remained in remission, whereas 81% of patients (13/16) in 
the placebo group had a disease flare, after a median time of 100 days from the start of placebo. As 
for safety, the proportion of patients experiencing at least one adverse event ranged from 77% in the 
third phase of the study to 100% in the second phase. Interestingly, during the same phase, adverse 
events were also recorded in 88% of patients treated with placebo. Most frequent adverse events 
included nasopharyngitis, rhinitis, diarrhea, nausea, influenza, bronchitis, headache, and vertigo. 
Overall, 9 patients experienced serious adverse events. There were no reports of severe injection-site 
reactions. Furthermore, no safety issues emerged regarding blood monitoring and urinalysis. In a 
phase II open-label study on 7 pediatric patients with CAPS (5 children with MWS and 2 adolescents 
with NOMID) [27], CANA (2 mg/kg s.c. for patients weighing ≤ 40 kg or 150 mg s.c. for patients 
weighing > 40 kg) led to a complete response within 7 days after the first dose in all cases. According 
to physicians’ assessments, a relevant improvement in symptoms occurred within 24 hours after the 
first dose. Six patients were retreated on relapse, and 4 achieved a second complete response within 
7 days following retreatment. CANA was generally well tolerated. Only one severe adverse event 
(vertigo) was reported. Most frequent adverse events were upper respiratory tract infection (n = 5), 
Figure 1. Strategies for IL-1 blockade with Anakinra and Canakinumab. (A) Interleukin (IL)-1 binds to
type 1 IL-1 receptor (IL-1R1) and to the adaptor protein, IL-1RAcP, in order to trigger signal transduction.
(B) The recombinant human IL-1R1 antagonist, Anakinra, directly competes with IL-1 for binding
to the IL-1R1, blocking the biological activity of IL-1. (C) The human monoclonal IgG1 antibody,
Canakinumab, selectively neutralizes IL-1β and inhibits its binding to the IL-1 receptor.
3. Cryopyrin-Associated Periodic Syndrome
CAPS includes a spectrum of apparently distinct inflammatory disorders of increasing
severity: Familial cold autoinflammatory syndrome (FCAS), Muckle-Wells syndrome (MWS), and
chronic infantile neurological, cutaneous, articular (CINCA) syndrome/neonatal-onset multisystem
inflammatory disease (NOMID), all caused by mutations in NLRP3, the gene encoding cryopyrin,
a component of the IL-1 inflammasome that regulates the production of IL-1β [25]. Therapeutic
strategies specifically aimed at blocking IL-1 have been widely evaluated in CAPS patients (Table 1).
Namely, the efficacy and safety profile of CANA in CAPS have been extensively assessed, both in
clinical trials as well as in the real clinical practice. In a 48-week double-blind placebo-controlled
randomized withdrawal study, the use of CANA (administered s.c. at the dose of 150 mg or 2 mg/kg
for patients weighing 40 kg or less) every 8 weeks was evaluated in a cohort of 35 CAPS patients [26].
Namely, 4 patients were aged 4 to 16 years, whereas the remaining 31 patients were aged 17 to
75 years. Of them, 26 had history of a previous anti-IL1 treatment. A single dose of CANA accounted
for complete response in 34 patients (97%); of note, CAPS symptoms significantly improved within
24 h in patients who had a response. Regarding patients entering the double-blind phase, all the
15 patients continuing CANA treatment remained in remission, whereas 81% of patients (13/16) in
the placebo group had a disease flare, after a median time of 100 days from the start of placebo. As
for safety, the proportion of patients experiencing at least one adverse event ranged from 77% in the
third phase of the study to 100% in the second phase. Interestingly, during the same phase, adverse
events were also recorded in 88% of patients treated with placebo. Most frequent adverse events
included nasopharyngitis, rhinitis, diarrhea, nausea, influenza, bronchitis, headache, and vertigo.
Overall, 9 patients experienced serious adverse events. There were no reports of severe injection-site
reactions. Furthermore, no safety issues emerged regarding blood monitoring and urinalysis. In a
phase II open-label study on 7 pediatric patients with CAPS (5 children with MWS and 2 adolescents
with NOMID) [27], CANA (2 mg/kg s.c. for patients weighing ≤ 40 kg or 150 mg s.c. for patients
weighing > 40 kg) led to a complete response within 7 days after the first dose in all cases. According
to physicians’ assessments, a relevant improvement in symptoms occurred within 24 h after the first
dose. Six patients were retreated on relapse, and 4 achieved a second complete response within 7 days
following retreatment. CANA was generally well tolerated. Only one severe adverse event (vertigo)
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was reported. Most frequent adverse events were upper respiratory tract infection (n = 5), rash (n = 4),
pharyngitis (n = 3), nasopharyngitis (n = 3), and vomiting (n = 3). In another open-label multicentre
phase III study conducted on 109 CANA-naïve adult and pediatric patients and 57 patients with
previous history of CANA treatment, CANA was administered at the dose of 150 mg or 2 mg/kg
every 8 weeks for up to 2 years [28]. Among CANA-naïve patients, complete response was achieved
in 85 cases (78%), 79 of which occurred within the first 8 days of treatment. The other 23 patients
who did not achieve complete response showed variable disease improvement. Data of the relapse
assessment were available for 141 patients; 90% of them did not relapse, whereas 14 had a clinical
relapse on at least one occasion. Overall, the median duration of treatment was 414 days (29–687 days)
for the entire cohort, and 290 days (29–625 days) for pediatric patients. In order to control disease,
higher doses were required in pediatric cases (≤ 40 kg) compared with adults, and in patients with
NOMID compared with other phenotypes. Overall, 40 patients needed dose (or dose frequency)
adjustments to control the disease. Overall, 90.4% of patients (n = 150) experienced at least one adverse
event. Most frequent adverse events included headache (n = 34), rhinitis (n = 27), arthralgia (n = 24),
bronchitis (n = 18), diarrhea (n = 18), and upper respiratory tract infections (n = 17). Eighteen patients
experienced at least one severe adverse event. In the pediatric cohort, six serious adverse events
were reported, related to tonsillitis (n = 3), severe intra-abdominal abscess following appendicitis,
severe bronchitis, and pneumonia. In a double-blind placebo-controlled randomized withdrawal study
by Koné-Paut et al. [29], 35 CAPS patients (of whom 5 were pediatric) received CANA 150 mg s.c.
every 8 weeks. According to the study protocol, a double-blind placebo-controlled withdrawal phase
was performed from week 9 to 24, whereas in the open-label phase from week 24 to 48 all patients
resumed CANA. On day 8, 89% of patients had minimal or no disease activity. By day 8, clinical
response was associated with a decrease of inflammatory markers, and considerable improvement in all
36-item Short-Form Health Survey (SF-36) domain scores. Response was sustained in patients treated
with 8-weekly CANA, whereas it was rapidly lost during the placebo-controlled phase in patients
receiving placebo and regained following CANA resumption. The 48-week treatment with CANA
was generally well tolerated. Only two patients experienced serious adverse events. Namely, one
patient had recurrent antibiotic-resistant lower urinary tract infection and sepsis, which required
CANA discontinuation; vertigo and increased intraocular pressure, acute glaucoma, and unilateral
blindness (complications of CAPS) were observed in the second patient. In an open-label study on
19 Japanese patients aged 2 to 48 years affected by NOMID (n = 12) or MWS (n = 7), CANA was
administered every 8 weeks for 24 weeks, at the dose of 150 mg s.c. or 2 mg/kg for patients with a body
weight over and under 40 kg, respectively [30]. Complete response was achieved in 18 out of 19 patients,
though with dose and/or frequency adjustments. At day 24, relapse occurred in four patients, whereas
one patient discontinued CANA before week 24. AID activity scores and inflammatory markers
significantly decreased following CANA treatment. Namely, mean C-reactive protein levels decreased
by 2.94 ± 2.99 mg/dL, dropping to 1.19 mg/dL at the end of the study compared to 4.52 mg/dL at
baseline. A similar trend was observed for serum amyloid-A (SAA) levels. Interestingly, anti-CANA
antibodies were detected in 3/19 patients, but the presence of these antibodies was not confirmed
in subsequent evaluations. As for the CANA safety profile, 18 patients (95%) experienced one or
more adverse events. Specifically, most common adverse events included nasopharyngitis (n = 7),
gastroenteritis (n = 6), upper respiratory tract infection (n = 3), and rhinorrhea (n = 3). Most adverse
events were mild, and only 3 were considered of moderate severity. Severe adverse events related to
diffuse vasculitis (n = 1) and pneumonia (n = 1) were also reported. Higher CANA doses (> 150 mg
or 2 mg/kg every 8 weeks) did not appear to be associated with a differential safety profile. In the
extension phase of this trial [31], both the efficacy and safety of CANA were evaluated over a 22
month-period. After 48 weeks of treatment, as well as at the end of the study period, all patients had
a complete response. All patients experienced at least one adverse event during the study, with the
most common event being upper respiratory tract infections (n = 14). Serious adverse events were
recorded in five patients, and included multiple infections, pneumonia, sinoatrial block, headache,
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asthma, and appendicitis. No permanent discontinuation of CANA due to adverse events was reported.
Regarding ANA, a 5-year prospective open-label cohort study evaluated the safety profile of ANA
in 43 CAPS patients (of whom 36 were children) [32]. The ANA starting dose ranged from 0.5 to
1.5 mg/kg/day, but was adjusted to 1.5 to 2.5 mg/kg/day during the follow-up period. The number of
adverse events reported during the 5-year study period was 1233, giving an overall reporting rate of
7.7 events per patient per year. Most frequent adverse events included headache (n = 21), arthralgia
(n = 18), and upper respiratory tract infections (n = 17). Serious adverse events occurred in 14 patients,
mostly within the first year of treatment and mostly related to infections. There were no deaths and all
adverse events resolved during the study period.
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Table 1. Main clinical trials evaluating the use of Anakinra (ANA) and Canakinumab (CAN) for the treatment of cryopyrin-associated periodic syndrome (CAPS),
tumor necrosis factor receptor-associated periodic syndrome (TRAPS), familial Mediterranean fever (FMF), and hyperimmunoglobulin D syndrome (HIDS)/mevalonate
kinase deficiency (MKD) in the pediatric population.
Authors Title Study Design Population Drug
Cryopyrin-Associated Periodic Syndrome (Including CINCA/NOMID and MWS)
Goldbach-Mansky et al.,
2006 [33]
Neonatal-onset multisystem inflammatory disease responsive to
interleukin-1beta inhibition. Clinical trial
Pediatric + adults (total
n = 18) ANA (1 to 2 mg/kg/day s.c.)
Goldbach-Mansky et al.,
2006 [33]
Neonatal-onset multisystem inflammatory disease responsive to
interleukin-1beta inhibition. Clinical trial
Pediatric (n = 15) +
adults (n = 3) ANA (1 to 2 mg/kg/day s.c.)
Imagawa et al., 2013 [30]
Safety and efficacy of Canakinumab in Japanese patients with phenotypes
of cryopyrin-associated periodic syndrome as established in the first
open-label, phase-3 pivotal study (24-week results).
Phase-3 pivotal study Pediatric + adults (totaln = 19)
CANA (150 mg s.c. (or 2 mg/kg for patients
with a body weight ≤ 40 kg) every 8 weeks for
24 weeks)
Koné-Paut et al., 2011 [29]
Sustained remission of symptoms and improved health-related quality of
life in patients with cryopyrin-associated periodic syndrome treated with
Canakinumab: Results of a double-blind placebo-controlled randomized
withdrawal study.
Double-blind
placebo-controlled
randomized withdrawal
study
Pediatric + adults (total
n = 35) CANA (150 mg s.c. at 8-week intervals)
Kuemmerle-Deschner et al.,
2011 [27]
Canakinumab (ACZ885, a fully human IgG1 anti-IL-1β mAb) induces
sustained remission in pediatric patients with cryopyrin-associated
periodic syndrome (CAPS).
Phase II, open-label
study Pediatric (n = 7)
CANA (2 mg/kg s.c. for patients ≤ 40 kg or
150 mg s.c. for patients > 40 kg; re-dosing upon
each relapse)
Kuemmerle-Deschner et al.,
2011 [28]
Two-year results from an open-label multicentre phase III study
evaluating the safety and efficacy of Canakinumab in patients with
cryopyrin-associated periodic syndrome across different severity
phenotypes.
Open-label, multicentre,
phase III study
Pediatric (n = 47) +
adults (n = 119)
CANA (s.c. 150 mg or 2 mg/kg
for patients ≤ 40 kg every 8 weeks for up to
2 years)
Kullenberg et al., 2016 [32] Long-term safety profile of Anakinra in patients with severecryopyrin-associated periodic syndrome.
Prospective, open-label,
single center trial
Pediatric (n = 36) +
adults (n = 7) ANA (starting dose 0.5 to 2.5 mg/kg/day)
Lachmann et al., 2009 [26] Use of Canakinumab in the cryopyrin-associated periodic syndrome.
Double-blind,
placebo-controlled,
randomized withdrawal
study
Pediatric (n = 4) + adults
(n = 31)
CANA (part 1: 150 mg s.c.; part 2: Either
150 mg of CANA or placebo every 8 weeks for
up to 24 week)
Sibley et al., 2017 [34] A 24-month open-label study of Canakinumab in neonatal-onsetmultisystem inflammatory disease. Open-label study
Pediatric (n = 2) + adults
(n = 4)
CANA (150 mg (or 2 mg/kg in patients ≤ 40 kg)
or 300 mg (or 4 mg/kg) with escalation up to
600 mg (or 8 mg/kg) every 4 weeks)
Wikén et al., 2018 [35] Development and effect of antibodies to Anakinra during treatment ofsevere CAPS: Sub-analysis of a long-term safety and efficacy study.
Post hoc analysis on
data from a prospective,
open-label, single-center,
clinical cohort study
Pediatric (n = 36) +
adults (n = 7)
ANA (1.0 to 2.4 mg/kg/day s.c., increased to 2.0
to 5.0 mg/kg/day according to clinical need
(median 3.1 mg/kg/day))
Yokota et al., 2017 [31]
Long-term safety and efficacy of Canakinumab in cryopyrin-associated
periodic syndrome: results from an open-label, phase III pivotal study in
Japanese patients.
Open-label, phase III
pivotal study
Pediatric + adults
(n = 35) CANA (2 to 8 mg/kg s.c. every 8 weeks)
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Table 1. Cont.
Authors Title Study Design Population Drug
Tumor Necrosis Factor Receptor-Associated Periodic Syndrome
De Benedetti et al., 2018 [36] Canakinumab for the treatment of autoinflammatory recurrent feversyndromes. Clinical trial
Pediatric (TRAPS n = 27)
+ adult (TRAPS n = 19) CANA (initial phase 150 mg/4 weeks)
Gattorno et al., 2008 [37] Persistent efficacy of Anakinra in patients with tumor necrosis factorreceptor-associated periodic syndrome. Clinical trial
Pediatric (n = 4) + adult
(n = 1) ANA (1.5 mg/kg/day)
Gattorno et al., 2017 [38]
Canakinumab treatment for patients with active recurrent or chronic TNF
receptor-associated periodic syndrome (TRAPS): An open-label, phase II
study.
Open-label, phase II
study
Pediatric (n = 6) + adults
(n = 14)
CANA (150 mg every 4 weeks for 4 months
(2 mg/kg for patients ≤ 40 kg))
Torene et al., 2017 [39] Canakinumab reverses overexpression of inflammatory response genes intumor necrosis factor receptor-associated periodic syndrome.
Open-label, multicentre,
proof-of-concept study
(gene analysis)
Pediatric (n.a.) + adults
(n.a.) CANA (150 mg every 4 weeks for 4 months)
Familial Mediterranean Fever
Brik et al., 2014 [40]
Canakinumab for the treatment of children with colchicine-resistant
familial Mediterranean fever: A 6-month open-label, single-arm pilot
study.
Open-label, single-arm
pilot study Pediatric (n = 7)
CANA (2 mg/kg (maximum 150 mg); the dose
was doubled to 4 mg/kg (maximum 300 mg) if
an attack occurred between day 1 and day 29)
De Benedetti et al., 2018 [36] Canakinumab for the treatment of autoinflammatory recurrent feversyndromes. Clinical trial
Pediatric (crFMF n = 29)
+ adult (crFMF n = 34) CANA (initial phase 150 mg every 4 weeks)
Gül et al., 2015 [41] Efficacy and safety of Canakinumab in adolescents and adults withcolchicine-resistant familial Mediterranean fever. Open-label pilot study
Pediatric (n.a.) + adults
(n.a.)
CANA (3 injections 150 mg s.c. injections every
4 weeks)
Hyperimmunoglobulin D Syndrome/Mevalonate Kinase Deficiency
Arostegui et al., 2017 [42]
Open-label phase II study to assess the efficacy and safety of
Canakinumab treatment in active hyperimmunoglobulinemia D with
periodic fever syndrome.
Clinical trial Pediatric (n = 6) + adults(n = 3) CANA (300 mg or 4 mg/kg every 6 weeks)
De Benedetti et al., 2018 [36] Canakinumab for the treatment of autoinflammatory recurrent feversyndromes. Clinical trial
Pediatric (MKD n = 54) +
adult (MKD n = 18) CANA (initial phase 150 mg/4 weeks)
ANA: Anakinra; CANA: Canakinumab; n.a.: not applicable; s.c.: subcutaneous.
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We report below, distinctly, the most severe forms of CAPS, including CINCA/NOMID and MWS,
focusing on the main studies in which ANA and CANA were employed.
CINCA/NOMID represents the most severe form of CAPS and is characterized by the triad of
cutaneous urticarial-like rash, arthropathy, and central nervous system (CNS) involvement, in association
with typical dysmorphic features, including frontal bossing and saddle back nose. CNS manifestations
encompass chronic aseptic meningitis leading to brain atrophy and sensorineural hearing loss. Anti-IL-1
treatment represents the standard therapy for this condition. A trial by Goldbach-Mansky et al. evaluated
both the efficacy and safety of ANA (1 to 2 mg/kg s.c.) in 18 NOMID patients [33]. All patients had a
prompt clinical response to ANA. In detail, rash and conjunctivitis disappeared within three days and
all inflammatory markers, including SAA, rapidly dropped. After 3 months of treatment, 11 patients
underwent a withdrawal phase of a maximum of 7 days. Disease flare occurred in all except one
patient, after a median time of 5 days (2.5 to 7 days). ANA resumption was associated with a rapid
response, and improvements were maintained over the 6 month follow-up. As for specific CNS
response, ANA treatment was associated with a significant decrease from 0.5 to 0.1 (p < 0.001) in
the median daily headache scores (classified from 0 to 4 for increasing severity). In 12 patients in
whom cerebrospinal fluid was evaluated, intracranial pressure, protein levels, and white-cell counts
also decreased significantly. Furthermore, brain magnetic resonance imaging showed a relevant
improvement in cochlear and leptomeningeal lesions as compared with baseline. Adverse events
reported during ANA treatment included upper respiratory infections (n = 15), urinary tract infections
(n = 2), and dehydration from nonbacterial diarrhea requiring hospitalization (n = 1). Localized,
injection-site erythematous reactions were reported in eight cases. However, none of the patients
discontinued drug treatment. The use of ANA in NOMID is further supported by evidence coming
from four observational studies [43–45] as well as from different isolated experiences (see details in
Table 1).
In a 24-month open-label phase I/II study [34], six patients aged 11 to 34 years were treated
with CANA 150 mg (or 2 mg/kg in patients ≤ 40 kg) or 300 mg (or 4 mg/kg) with escalation up to
600 mg (or 8 mg/kg) every 4 weeks, after discontinuation of previous ANA treatment. CANA led
to a significant improvement in all patients, with four patients having inflammatory remission at
month 6. CNS remission was not achieved by any of the six patients. However, five patients had
a significant improvement in their headache diary scores, and the other patient had a normal CSF
leucocyte count, albeit showing a persistent headache. Overall, CANA was well tolerated. Only
one severe adverse event related to a methicillin-resistant Staphylococcus aureus abscess was recorded.
Twelve infection-related adverse events occurred in six patients.
MWS is a rare autosomal dominant disease belonging to the family of CAPS: Its manifestations
include urticaria-like rashes, arthralgia, progressive sensorineural deafness, episodic fever, and renal
amyloidosis. IL-1 inhibitors have been shown to be revolutionary in MWS [46]. The use of ANA in
MWS was evaluated in a single-center observational study on 12 patients (5 children and 7 adults)
with severe MWS [47] (see Table 1). After 2 weeks of treatment, a significant decrease in disease
activity was reported, leading to significant improvement of organ manifestations as well as improved
inflammatory parameters. Treatment was well tolerated, and no severe adverse events were reported.
In another single-center open-label prospective observational study on patients diagnosed with active
MWS between 2004 and 2008, ANA was started in five pediatric and seven adult patients, whereas
CANA was initiated in six children and eight adults [48]. Both treatments led to a significant reduction
of disease activity and inflammatory parameters. After a mean time of 12 months (range 5 to 14 months)
for ANA and 11 months (6 to 15 months) for CANA, disease remission was achieved in 75% and 93%
of patients, respectively. No detectable difference in treatment efficacy was found when comparing
anti-IL-1 naïve versus rollover patients (i.e., treated with CANA after ANA discontinuation). In the
ANA cohort, no serious adverse events were observed. Mild adverse events included injection-site
reactions in five patients and mild upper respiratory infections in four patients, respectively. In the
CANA cohort, vertigo occurred in one patient and required hospitalization. No injection-site reactions
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were observed. Other adverse events included mild upper respiratory tract symptoms in four patients
and transient headache in two patients. The use of ANA in MWS is further supported by evidence
deriving from five case reports [49–53].
4. Tumor Necrosis Factor Receptor-Associated Periodic Syndrome
TRAPS is the most frequent autosomal dominant autoinflammatory disorder, which is caused
by mutations in the TNFRSF1A gene, encoding the 55-kD type-1 receptor of tumor necrosis factor
(TNF)-α [54]. The average age at disease onset is around 3 years; however, adult onset has been
described up to the sixth decade of life. This disease is clinically characterized by recurrent episodes
of long-lasting fever and inflammation involving different organs, such as the skin, gastrointestinal
tract, serous membranes, joints, muscles, and eyes. Inflammatory attacks are initially responsive to
corticosteroids, but the progressive loss of response and recurrence of uncontrolled attacks is further
associated with the development of secondary amyloidosis [55]. As IL-1-mediated inflammation is
directly involved in the pathogenesis of this syndrome, anti-IL-1 treatments are gaining a relevant
role in the management of this disorder (Table 1) [56,57]. Namely, Gattorno et al. evaluated the use
of ANA in four children and one adult with TRAPS [37]: All patients had a rapid response to ANA,
with a disappearance of symptoms and normalization of inflammatory parameters, including SAA.
According to the study protocol, ANA was discontinued after 15 days of treatment. In all cases, a
disease relapse was observed, within a mean time of 6 days (range, 3 to 8 days), whereas reintroduction
of ANA was associated with a regain of disease control. Over a mean follow-up of 11 months, no fever
episodes as well as no disease-related clinical manifestations were observed. The only adverse events
reported were cutaneous reactions, including rash, pain, and itching, all occurring during the first
week of treatment. Use of CANA in TRAPS has been evaluated in an open-label phase II study on
20 patients aged 7 to 78 years, with active recurrent or chronic TRAPS [38]. CANA, at the dose of 150 mg
every 4 weeks for 4 months or 2 mg/kg for patients weighing 40 kg or less, induced clinical remission
(Physician’s Global Assessment score ≤ 1) and full or partial serological remission within day 15 in 95%
of patients (n = 19). Responses to CANA occurred rapidly, with a median time to clinical remission
of 4 days (3–8 days). Furthermore, a significant improvement in the quality of life was also reported.
According to the study protocol, CAN was withdrawn after 4 months of treatment: All patients relapsed
following CANA discontinuation after a median time of 91.5 days (range of 65 to 117 days). However,
CANA was well tolerated. All patients reported at least one adverse event, and most common events
were nasopharyngitis (n = 12), abdominal pain (n = 11), headache (n = 11), and oropharyngeal pain
(n = 10). Serious adverse events were reported in seven patients, and included pericarditis, abdominal
pain, diarrhea, intestinal obstruction, vomiting, upper respiratory tract infection, meniscus injury,
hypertriglyceridemia, and hyperkalemia. No significant changes in laboratory, clinical, and vital
parameters were reported, and no patients developed anti-drug antibodies.
5. Familial Mediterranean Fever
FMF is the most frequent autosomal recessive autoinflammatory disorder, characterized by
self-limited episodes of fever and polyserositis, which may also lead to long-term complications,
such as renal amyloidosis [58,59]. Although its pathogenesis is not fully understood, the MEFV gene
encodes mutant pyrins, crucial players in the regulation of innate immunity, which lead to uncontrolled
production of IL-1 [59]. Use of CANA in colchicine-resistant FMF (crFMF) is supported by three clinical
trials (Table 1). In the 6-month open-label, single-arm pilot study by Brik et al. [40], seven children
with crFMF were treated with subcutaneous injections of CANA at the dose of 2 mg/kg (maximum
150 mg), 4 weeks apart. Six patients experienced a reduction of 76% to 100% of FMF attacks, and
three did not experience any attacks during the treatment phase. After the last CANA injection, five
participants developed an attack, after a median time of 25 days (range of 5 to 34 days). Overall,
11 adverse events were reported in four patients, including two cases of infections. All adverse events
were mild, except a moderate streptococcal throat infection. No significant laboratory abnormalities
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and formation of neutralizing anti-CANA antibodies were reported. In another open-label trial on nine
adolescents and adults with crFMF [41], CANA accounted for a reduction of 50% or more in attack
frequency in all treated patients, with only one patient experiencing an attack during the treatment
period. Furthermore, following CANA administration, a significant improvement was observed in
both the physical and mental component assessed by SF-36. Following the last CANA injection,
five patients had an attack, after a median time of 71 days (range of 31 to 78 days). Eight patients (89%)
experienced one or more adverse events. Namely, the most frequent adverse events were headache
(n = 4), and respiratory tract infections. Other adverse events included, anxiety, hidradenitis, pruritus,
tooth infection, and vomiting, all reported in one case each. Effectiveness and safety of CANA in
crFMF is further supported by two long-term retrospective observational studies on 15 children [60]
and 14 adolescent or adult patients [61], respectively. On the other hand, the use of ANA in FMF is
mainly supported by observational evidence. In a study by Bas¸aran et al. [62], eight children and
adolescents with crFMF were treated with ANA (1 mg/kg/day to 3 mg/kg/day). A switch to CANA
was required in four cases, due to noncompliance to daily injections in three cases and clinical and
laboratory worsening in one case. Overall, the use of anti-IL-1 drugs was beneficial to all patients,
both in terms of a reduction of attack frequency and normalization of inflammatory parameters. No
severe adverse events were reported, and only one patient experienced a local injection-site erythema
with ANA.
Yet, in another retrospective study by Cetin et al. [63] conducted on 20 patients with crFMF,
4 pediatric patients were treated with ANA or CAN (in two cases each). In two children treated with
ANA, the number of monthly attacks decreased from 4 to 0 in one case and from 1 to 0 in the other one.
ANA was continued for 12 and 7 months, respectively, and was still ongoing at the end of the study.
Similarly, CANA also accounted for a significant reduction both in the rate of monthly and annual
attacks. No adverse skin or allergic events was reported. Biopsy-proven amyloidosis was present in one
child treated with CANA, with a significant decrease of urinary protein excretion (from 25.6 mg/m2/h
to 12 mg/m2/h before versus after CANA treatment, respectively). In the retrospective study by
Özçakar et al. [64], three pediatric patients suffering from crFMF were treated with ANA and one case
with CAN. Three of them (two treated with ANA and one with CANA) had concomitant FMF-related
amyloidosis. Among the three patients treated with ANA, the occurrence of attacks was significantly
reduced. However, for the two patients with amyloidosis, one needed renal transplantation and the
other had end-stage renal disease. In the patient treated with CANA, the frequency of disease attacks
was significantly reduced (from 24 attacks/year to 0), and partial remission of nephrotic syndrome was
achieved. None of these patients experienced drug-related adverse events.
6. Hyperimmunoglobulin D Syndrome/Mevalonate Kinase Deficiency
HIDS/MKD is an autosomal recessive disorder caused by mutations in the gene encoding
the enzyme mevalonate kinase, directly involved in cholesterol and isoprenoid biosynthesis.
This autoinflammatory disease usually starts in the first year of life and is characterized by lifelong
recurrent fever episodes (every 4 to 6 weeks), typically lasting from 3 to 7 days [65,66]. The clinical
signs range from the milder HIDS to its most severe expression, named “mevalonic aciduria”. The most
frequent symptoms during febrile attacks, sometimes precipitated by vaccinations, infections, emotional
stress, trauma, or surgery, are abdominal pain, diarrhea, vomiting, arthralgia, lymphadenopathy,
heterogeneous skin lesions, and aphthous ulcers [4]. An increase in mevalonic acid and activation
of small GTPases result in IL-1 overexpression via caspase-1 activation. Therefore, short-term IL-1
blockade may be effective for stopping inflammatory attacks [2]. To date, two clinical trials have
evaluated the use of the IL-1 inhibitor, CANA, in this condition, whereas no controlled clinical trial on
ANA has been conducted (Table 1). Namely, in the open-label phase II study by Arostegui et al. [42],
CANA was administered subcutaneously at the dose of 300 mg (or 4 mg/kg for patients weighing≤ 40 kg)
every 6 weeks to six pediatric patients and three adults with active HIDS. In this cohort, the first CANA
injection led to good or excellent control of the disease, with a median time to disease resolution of
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3 days. Furthermore, CANA accounted for a significant reduction in the severity or disappearance of
HIDS features, including fever, lymphadenopathy, abdominal pain, and aphthous ulcers. According to
the study protocol, CANA was discontinued after 6 months. Seven out of nine patients experienced
a relapse following CANA discontinuation, the median time to relapse being 110 days (range of
62 to 196 days). As for its safety profile, all nine patients experienced at least one adverse event
during the study period, albeit only one was judged as drug-related (i.e., non-serious fungal vaginitis).
Overall, 98 adverse events (of whom 14 serious) were observed. Most frequent non-serious adverse
events were related to infections and required systemic antibiotics in most cases. As for serious
adverse events, 8 out of 14 events included acute peritonitis, anemia, bacteremia due to Streptococcus
pneumoniae, gastrointestinal bleeding, hypertensive crisis, pneumonia, and severe anemia, which
occurred in the same patient. Another patient was hospitalized due to hidradenitis suppurativa, and
one patient developed cellulitis in the left arm. No death was reported, and no patient required drug
discontinuation because of adverse events. Furthermore, no relevant change in clinical laboratory
parameters and vital signs was observed.
Use of ANA in the treatment of pediatric HIDS/MKD is supported only by observational evidence.
Specifically, two studies evaluated both the efficacy and safety of ANA for this condition. In the
prospective observational study by Bodar et al. [67], 11 patients with HIDS (4 pediatric patients aged 5
to 17) were treated with either continuous (n = 3) or on-demand (n = 8) ANA (starting at first symptoms
of an attack, 100 mg/day or 1 mg/kg/day for 5 to 7 days). In the two pediatric patients with mevalonic
aciduria, continuous ANA treatment induced partial remission only in one case, and no response in the
other one. Among the other nine patients, continuous ANA treatment induced complete remission, but
was further discontinued for safety reasons. Among the nine patients with on-demand therapy, ANA
induced a clinical response in 8 out of 12 attacks, but did not impact on its frequency. No major adverse
events were observed; local injection-site reactions as well as mild upper respiratory tract infections
were the only adverse events. Of note, treatment discontinuation was required in one patient. In the
cohort of 103 adult and pediatric HIDS patients investigated in the observational study by van der
Hilst et al., the use of ANA was reported in 11 cases: Among them, four achieved a good response to
treatment, three a partial response, whereas the remaining four had no response to therapy [68]. Use of
both ANA and CANA has been further evaluated in an observational study by Galeotti et al. [69]:
Eleven French adult and pediatric patients were treated with either ANA (n = 9) or CANA (n = 6,
of whom four following ANA treatment), reaching a complete and partial remission in four and seven
cases, respectively. Anti-IL-1 treatment was also associated with a decrease in a 12-item clinical score,
in the number of days with fever during attacks as well as in the level of inflammatory parameters.
Both drugs were well tolerated. During ANA treatment, four patients experienced injection-site
reactions, whereas shivers and hypothermia after the first injection and bacterial pneumonia were
reported in one patient each. As for CANA, adverse events included injection-site reaction (n = 1),
recurrent pharyngitis (n = 1), and transient hepatitis (n = 2, one of whom was without confirmation of
viral or autoimmune etiology). No alterations in hematological and urinary parameters were reported.
Yet, in a national Japanese survey conducted on 10 pediatric patients suffering from MKD, the use of
anti-IL-1 treatment was reported in two patients [70]: In both patients, initial ANA treatment accounted
for partial response, whereas a switch to CANA led to a complete response. During anti-IL-1 treatment,
transaminase elevation and arthritis were reported in one patient each.
7. Additional Evidence on IL-1 Inhibition in Autoinflammatory Diseases
Beside the above summarized evidence for specific AIDs, the use of anti-IL-1 has been evaluated
also in mixed cohorts of patients with different conditions.
A retrospective chart review by Ozen et al. evaluated the treatment pattern of 134 patients with
FMF (n = 49), TRAPS (n = 47), or HIDS/MKD (n = 38), highlighting the central role of anti-IL-1 agents
in the management of these conditions [71]. Similarly, data derived from the Eurofever Registry and
related to 496 patients with FMF, CAPS, TRAPS, MKD, pyogenic arthritis-pyoderma gangrenosum-acne
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(PAPA) syndrome, deficiency of IL-1 receptor antagonist (DIRA), NLRP12-related autoinflammatory
disorder, and periodic fever-aphthosis-pharyngitis-adenitis (PFAPA) syndrome pointed out the key-role
of IL-1 blockade for DIRA and CAPS, as well as for cases of poorly controlled MKD, TRAPS, PAPA,
and crFMF [72]. According to an Italian study aimed at evaluating the use of IL-1 inhibitors among
475 patients (of whom 111 were aged 16 or less), 86% and 56% of all treatments with ANA and CANA,
respectively, were mainly related to adult onset Still’s disease (18.5%), SJIA (13.5%), Behçet’s disease
(9.7%), FMF (7.6%), idiopathic recurrent acute pericarditis (5.6%), and TRAPS (5.0%) in the ANA group,
and to Behçet’s disease (14.3%), TRAPS (13.3%), FMF (5.7%), and HIDS (3.8%) in the CANA one [73].
Efficacy and safety of ANA in patients with AIDs is further supported by the result of a French
nationwide survey on 189 patients [74]. On the other hand, damage caused by amyloid deposits in
AIDs seems not to improve with anti-IL 1 treatment [75].
In a recent clinical trial by De Benedetti et al. [36], 63 patients with crFMF (29 were children), 72
with MKD (54 children), and 46 with TRAPS (27 children) were randomized to receive CANA 150 mg
s.c. or placebo every 4 weeks, with an add-on injection of 150 mg of CANA in the case of no flare
resolution. At week 16, the proportion of patients with complete response was significantly higher
in the CANA group if compared with the placebo group: Sixty-one percent versus 6% for patients
with crFMF (p < 0.001), 35% versus 6% for MKD (p = 0.003), and 45% versus 8% for TRAPS (p = 0.006).
Considering also patients who required an increase in the CANA dose, a complete response was
achieved in 71% of patients with crFMF, in 57% of patients with MKD, and in 73% of those with
TRAPS. After 16 weeks, disease control was maintained in 46%, 23%, and 53% of patients with crFMF,
MKD, and TRAPS, respectively. Numbers of adverse events observed during CANA treatment were
332, 613, and 265 among patients with crFMF, MKD, and TRAPS, respectively. Namely, numbers of
adverse events related to infections were 79, 160, and 58 in the three disease groups. As for events
unrelated to infections, most frequent adverse events included abdominal pain, headache, arthralgia,
and injection-site reactions. This study led to market authorization of CANA for the three conditions.
8. Systemic Juvenile Idiopathic Arthritis
SJIA is an inflammatory disease associated with dysregulation of the innate immune system [7,9].
The disease is characterized by fever, lymphadenopathy, arthritis, rash, and serositis. Furthermore,
complications of SJIA include invalidating arthritis and MAS, a condition characterized by unremitting
high fever, pancytopenia, hepatosplenomegaly, hepatic dysfunction, encephalopathy, coagulation
abnormalities, and increased levels of ferritin. As IL-1 and IL-6 have been shown to play a primary
role in the pathogenesis of SJIA, anti-IL-1 treatments as well as anti-IL-6 drugs represent promising
therapeutic strategies for the control of this disease [7,9]. The use of IL-1 inhibitors, ANA and CANA,
in SJIA has been extensively evaluated, both in clinical trials and observational studies (Table 2). In a
study by Gattorno et al. [76], ANA (at the starting dosage of 1 mg/kg/day, for a maximum of 100 mg)
was administered to 22 patients aged 1 to 19 years. Within the first week of treatment, two distinct
patterns of response to ANA could be distinguished. One group of 10 patients achieved prompt
improvement of systemic and articular manifestations as well as improved inflammatory parameters,
maintaining complete disease control during a mean follow-up of 1.36 years (range of 0.3 to 2.59 years).
On the other hand, a second group of 11 patients experienced a variable response to ANA, with an
improvement soon after treatment began, but with a general tendency towards relapses, particularly at
the articular level. These two clusters appeared to be characterized by different clinical features, in
particular patients with complete response had a significantly lower number of active joints and an
increased absolute neutrophil count.
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Table 2. Main clinical trials evaluating the use of Anakinra (ANA) and Canakinumab (CANA) for the treatment of systemic juvenile idiopathic arthritis (SJIA) in the
pediatric population.
Systemic Juvenile Idiopathic Arthritis
Authors Title Study Design Population Drug
Brachat et al., 2017 [77]
Early changes in gene expression and inflammatory
proteins in systemic juvenile idiopathic arthritis patients on
Canakinumab therapy.
Gene expression analysis (data
from the two phase-3 trials
evaluating CANA for SJIA)
Pediatric (n.a.)
CANA
(Trial 1: Patients were randomly assigned to a single s.c.
dose of CANA (4 mg/kg) or placebo.
Trial 2: Open-label phase (s.c. CANA 4 mg/kg every
4 weeks for up to 32 weeks) + withdrawal phase)
Feist et al., 2018 [78]
Efficacy and safety of Canakinumab in patients with Still’s
disease: Exposure-response analysis of pooled systemic
juvenile idiopathic arthritis data by age groups.
Pooled results of clinical trials
Pediatric (n = 216) +
adolescents (n = 56) +
adult (n = 29)
CANA
(Study 1: Single s.c. CANA at 4 mg/kg (maximum of
300 mg) or placebo;
Study 2: CANA 4 mg/kg (maximum dose of 300 mg) every
4 weeks for up to 8 months + second double-blind
randomized placebo-controlled phase;
Study 3: S.c. CANA 4 mg/kg every 4 weeks for 12 weeks
(patients had received CANA in either Study 1 or Study 2,
with an additional cohort of CANA-naïve patients);
Study 4: Dose-ranging study (0.5–9 mg/kg)
Gattorno et al., 2008 [76]
The pattern of response to anti-interleukin-1 treatment
distinguishes two subsets of patients with systemic-onset
juvenile idiopathic arthritis.
Clinical study Pediatric (n = 22) ANA(starting dosage of 1 mg/kg/day, s.c. (maximum 100 mg))
Grom et al., 2016 [79]
Rate and clinical presentation of macrophage activation
syndrome in patients with systemic juvenile idiopathic
arthritis treated with Canakinumab.
Pooled analysis Pediatric (n = 21) CANA (n.a.)
Ilowite et al., 2009 [80]
Anakinra in the treatment of polyarticular-course juvenile
rheumatoid arthritis: Safety and preliminary efficacy
results of a randomized multicenter study.
2-week open-label run-in phase Pediatric (n = 86) ANA (1 mg/kg daily, maximum 100 mg/day)
Kimura et al., 2017 [81]
Pilot study comparing the Childhood Arthritis &
Rheumatology Research Alliance (CARRA) systemic
juvenile idiopathic arthritis consensus treatment plans.
Pilot interventional study Pediatric (n = 30; IL-1inhibitors n = 12)
ANA (CANA)
(median initial dose of ANA 2.93 (IQR 2–3.6))
Quartier et al., 2011 [82]
A multicentre randomized double-blind placebo-controlled
trial with the interleukin-1 receptor antagonist Anakinra
in patients with systemic-onset juvenile idiopathic arthritis
(ANAJIS trial).
Multicentre, randomized,
double-blind,
placebo-controlled trial
Pediatric (n = 24) ANA (2 mg/kg s.c. daily, maximum 100 mg)
Ruperto et al. (trial 1),
2012 [83]
Two randomized trials of Canakinumab in systemic
juvenile idiopathic arthritis. 2 phase III trials Pediatric (n = 84 + 177) CANA (s.c., 4 mg/kg per month (maximum dose, 300 mg))
Ruperto et al. (trial 2),
2012 [84]
A phase II, multicenter, open-label study evaluating dosing
and preliminary safety and efficacy of Canakinumab in
systemic juvenile idiopathic arthritis with active systemic
features.
Phase II, multicenter, open-label,
dosage-escalation study Pediatric (n = 23) CANA (single s.c. dose of 0.5 to 9 mg/kg)
Ruperto et al., 2018 [85]
Canakinumab in patients with systemic juvenile idiopathic
arthritis and active systemic features: Results from the
5-year long-term extension of the phase III pivotal trials.
5-year long-term extension of
the phase III pivotal trials.
Pediatric (n = 177; 144 in
the long-term extension
phase)
CANA (4 mg/kg s.c. every 4 weeks (maximum dose
300 mg); in the long-term extension, tapered to 2 mg/kg
every 4 weeks in patients who were glucocorticoid free as
per physicians’ judgement)
ANA: Anakinra; CANA: Canakinumab; IQR: interquartile range; n.a.: not applicable; s.c.: subcutaneous.
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Another multicentre randomized double-blind placebo-controlled trial compared the efficacy of
ANA (2 mg/kg s.c. daily, maximum 100 mg) versus placebo in 24 SJIA patients aged 8.5 ± 4.5 years [82].
After 1 month of treatment, response (defined as a 30% improvement of the pediatric American College
of Rheumatology (ACR) criteria for JIA, resolution of systemic symptoms, and a decrease of at least
50% of inflammatory parameters compared with baseline) was achieved in 8 out of 12 patients treated
with ANA and only in 1 patient receiving placebo (p = 0.003). Ten patients were switched from placebo
to ANA; of them, nine achieved response within month 2. Fourteen adverse events were recorded in
the ANA group and 13 in the placebo group. No serious adverse event was reported. Namely, in the
ANA group, adverse events, including injection-site pain (n = 8), post-injection erythema (n = 3), and
infections involving gastrointestinal and upper respiratory tract (n = 2), were recorded.
In a multicenter double-blind trial on 50 patients aged 3 to 17 years with polyarticular-course JIA
(11 of whom had systemic onset), randomized to ANA (1 mg/kg/day, for a maximum of 100 mg) or
placebo [80], the three most common reported adverse events were injection-site reactions (12% in each
group), upper respiratory infections (16% versus 20% in the ANA and placebo groups, respectively),
and headache (24% versus 4%). No case of adverse event-related discontinuation of the blinded phase
was observed. In the subsequent extension phase of ANA treatment, the most common adverse
events reported were arthralgia (23%), fever (21%), and abdominal pain (16%), with three patients (7%)
requiring discontinuation of ANA because of safety issues.
In another pilot study evaluating different therapeutic strategies for treatment of SJIA [81], 12 out of
30 patients received IL-1 inhibitors (ANA as initial treatment, eventually switched to CANA). Of them,
two patients needed to add methotrexate, whereas two needed to switch to an IL-6 inhibitor. Overall,
clinical disease inactivity was reached in 42% of patients treated with IL-1 inhibitors. There were four
serious adverse events: Two resulted in hospitalization for intravenous antimicrobial therapy (cellulitis
in a child taking CANA and glucocorticoids, and varicella in a child taking ANA), one hospitalization
for appendicitis and appendectomy in a child on methotrexate and glucocorticoid, and one for MAS in
a child on tocilizumab. As for CANA, its efficacy and safety in SJIA has been extensively evaluated in
a pooled analysis of data coming from four trials [78,83–85]. CANA (mostly administered at the dose
of 4 mg/kg every 4 weeks) was given to a total population of 233 children, 60 young adolescents and
31 older adolescents or young adults. Within day 15 of treatment, at least 50% of patients in each age
group had absence of fever as well as ≥ 70% improvement according to the adapted ACR pediatric
response criteria. Responses were stable and maintained or improved over the 85 days of follow-up.
Similarly, clinical and laboratory findings also markedly improved in all age groups. Regarding safety,
adverse events were reported in 86.7% to 88.3% of patients in the different age groups, with 11%
to 19% of patients who experienced adverse events leading to treatment discontinuation. In all age
groups, most common adverse events were infections (70–76%), gastrointestinal disorders (52–58%),
and musculoskeletal or connective tissue disorders (51–55%). Other adverse events included disorders
of the skin, subcutaneous tissue, and respiratory tract. Serious adverse events were reported in 29% to
42% of patients, and included JIA reactivation, MAS, gastroenteritis, and Cytomegalovirus infection.
Beside the above mentioned evidence from clinical trials, the use of ANA and CANA in SJIA is also
supported by growing evidence coming from observational studies [79,86–93].
9. Kawasaki Disease
KD is an acute vasculitis of unknown etiology, which is typically observed in the pediatric
age. If untreated, patients with KD are at significantly higher risk of developing coronary artery
abnormalities, thromboembolic occlusions, and myocardial infarction, with subsequent increased
risk of mortality [94]. Many shortcomings still exist in studies aimed at defining the etiology of KD,
though different levels of evidence support the hypothesis that it is a complex disease with a unique
pathogenesis [95]. Intravenous immunoglobulins (IVIG) in association with aspirin represent the main
treatment for KD and their administration within the first 10 days following fever onset has been
associated with a 5-fold reduction in the risk of coronary artery aneurysms [96].
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The extent of acute phase response and a younger age at onset may be related to patients’
responsiveness to IVIG [97]. In particular, 10% to 15% of patients develop resistance to this treatment:
The prediction of IVIG resistance is a crucial issue for managing these children, as recognizing
high-risk patients should allow the administration of an intensified initial treatment in combination
with IVIG, and prevent coronary injuries [98]. Limited and local experiences suggest the possible benefit
of IL-1 inhibition in children with KD [99–104]. A retrospective case series by Koné-Paut et al. [105]
evaluated the use of ANA (2 to 8 mg/kg) in 11 children with KD aged 4 months to 9 years refractory to
standard treatment. Specifically, the main reasons for starting ANA were persistent inflammation,
progression of coronary dilations, and severe myocarditis with cardiac failure. ANA proved to be
effective in controlling KD. Namely, all patients had fever resolution and a decrease of inflammatory
parameters. Furthermore, 10 out of 11 patients had a decrease in coronary artery dilations. The other
patient died suddenly due to massive pericardial effusion secondary to giant aneurysm rupture while
on anticoagulant treatment. To date, two trials with ANA in children with Kawasaki disease are
ongoing (NCT02179853 and NCT02390596).
10. Conclusions
Recent evidence from both observational studies and clinical trials have clarified the efficacy of
ANA and CANA in the main AIDs, also revealing a good safety profile with minor concerns regarding
tolerability. In particular, the major treatment-related side effects of ANA are skin reactions at the
injection-site. This high rate of injection-site reactions can become so irritating for pediatric patients that
they require treatment withdrawal. In this regard, convincing patients, especially children, to continue
therapy can be challenging. Reactions can be mitigated by the application of topical hydrocortisone or
anti-histamine cream, but it may not be enough [106]. On the other hand, the overall safety of CANA
has shown an excellent tolerability [107], as highlighted by very few discontinuation rates and few
injection-site reactions. However, a slightly increased rate of non-serious infections related to the
upper respiratory tract has been observed [26]. Although these two anti-IL1 agents represent the most
effective treatments available in AIDs and also a promising tool in refractory KD, the development of
novel pharmacological formulations that further reduce side effects in pediatric sceneries is expected.
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